Spore-casting outcomes: Histoplasma serology in lung nodule risk stratification.

IF 2.4 4区 生物学 Q3 MICROBIOLOGY
Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-28 DOI:10.1080/17460913.2026.2665041
Nicholas D Nassif, Elena K Roberts, Sheryl-Phuc N Vu, Keenan W Taylor
{"title":"Spore-casting outcomes: Histoplasma serology in lung nodule risk stratification.","authors":"Nicholas D Nassif, Elena K Roberts, Sheryl-Phuc N Vu, Keenan W Taylor","doi":"10.1080/17460913.2026.2665041","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lung nodule evaluation is a vital practice in pulmonary medicine. While biopsy remains the diagnostic gold standard, it carries procedural risks. In regions endemic for fungal disease, low-cost, noninvasive testing may help reduce unnecessary procedures.</p><p><strong>Aim: </strong>We seek to evaluate the association between positive endemic histoplasma antibody titers and non-cancerous pathology in patients with pulmonary nodules. Methods: We conducted a simple, retrospective, single-center study of patients diagnosed with solitary (R91.1) or multiple (R91.8) pulmonary nodules. Data collected included Histoplasma antibody results, pathologic diagnoses when available, PET-CT, and clinical course (follow-up CT scans).</p><p><strong>Results: </strong>Positive Histoplasma antibody testing demonstrated an inverse relationship with malignant pathology. However, this association did not reach statistical significance. Conclusions: Histoplasma antibody titers may help identify patients with pulmonary nodules who are less likely to have malignancy, potentially supporting conservative monitoring over biopsy in selected cases. Larger, prospective studies are needed to determine the clinical utility of fungal testing in lung nodule management.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"423-428"},"PeriodicalIF":2.4000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/17460913.2026.2665041","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lung nodule evaluation is a vital practice in pulmonary medicine. While biopsy remains the diagnostic gold standard, it carries procedural risks. In regions endemic for fungal disease, low-cost, noninvasive testing may help reduce unnecessary procedures.

Aim: We seek to evaluate the association between positive endemic histoplasma antibody titers and non-cancerous pathology in patients with pulmonary nodules. Methods: We conducted a simple, retrospective, single-center study of patients diagnosed with solitary (R91.1) or multiple (R91.8) pulmonary nodules. Data collected included Histoplasma antibody results, pathologic diagnoses when available, PET-CT, and clinical course (follow-up CT scans).

Results: Positive Histoplasma antibody testing demonstrated an inverse relationship with malignant pathology. However, this association did not reach statistical significance. Conclusions: Histoplasma antibody titers may help identify patients with pulmonary nodules who are less likely to have malignancy, potentially supporting conservative monitoring over biopsy in selected cases. Larger, prospective studies are needed to determine the clinical utility of fungal testing in lung nodule management.

孢子铸造结果:肺结节危险分层的组织浆血清学。
背景:肺结节评估是肺医学的重要实践。虽然活组织检查仍然是诊断的金标准,但它存在程序风险。在真菌病流行的地区,低成本、无创检测可能有助于减少不必要的程序。目的:我们试图评估阳性地方性组织浆抗体滴度与肺结节患者非癌性病理之间的关系。方法:我们对诊断为单发(R91.1)或多发(R91.8)肺结节的患者进行了一项简单、回顾性、单中心研究。收集的数据包括组织浆体抗体结果、可用的病理诊断、PET-CT和临床病程(随访CT扫描)。结果:组织浆抗体阳性与恶性病理呈负相关。然而,这种关联并没有达到统计学意义。结论:组织浆抗体滴度可能有助于识别不太可能有恶性肿瘤的肺结节患者,潜在地支持在选定病例中保守监测活检。需要更大规模的前瞻性研究来确定真菌检测在肺结节治疗中的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future microbiology
Future microbiology 生物-微生物学
CiteScore
4.90
自引率
3.20%
发文量
134
审稿时长
6-12 weeks
期刊介绍: Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书